General
Preferred name
FIMEPINOSTAT
Synonyms
CUDC-907 ()
PI3K/HDAC Inhibitor ()
CUDC 907 ()
Fimepinostat (CUDC-907) ()
CUDC907 ()
P&D ID
PD010586
CAS
1339928-25-4
Tags
available
drug candidate
Drug indication
Diffuse large B-cell lymphoma
Solid tumour/cancer
Acute myelogenous leukaemia
Neuroblastoma
Lymphoma
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
CUDC-907 is an investigational dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K) activity . The compound is orally available.
DESCRIPTION
Fimepinostat (CUDC-907) is an investigational dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K) activity . The compound is orally available.
(GtoPdb)
DESCRIPTION
Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3K¦Á/PI3K¦Â/PI3K¦Ä and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.
PRICE
98
DESCRIPTION
CUDC-907 is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types. This may prevent growth of PI3K and/or HDAC-expressing tumor cells. CUDC-907 shows an increased inhibition of tumor cell growth and induction of apoptosis when compared to inhibitors that target either PI3K or HDAC.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Fimepinostat (CUDC 907) is an orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan-histone deacetylase (HDAC) enzymes, with potential antineoplastic activity. Upon oral administration, CUDC-907 inhibits the activity of both PI3K class I isoforms and HDAC, thereby preventing the activation of the PI3K-AKT-mTOR signal transduction pathway that is often overactivated in many cancer cell types.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
32
Organisms
1
Compound Sets
15
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LINCS compound set
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
508.16
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
4
cLogP
2.14
TPSA
138.72
Fraction CSP3
0.3
Chiral centers
0.0
Largest ring
6.0
QED
0.28
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
HDAC
HDAC1
HDAC10
HDAC11
HDAC2
HDAC3
PI3K
HDAC2, PIK3R1
Apoptosis related,HDAC,PI3K
MOA
PI3K inhibitor
Pathway
Chromatin/Epigenetic
DNA Damage/DNA Repair
PI3K/Akt/mTOR signaling
Cell Cycle/DNA Damage
Epigenetics
PI3K/Akt/mTOR
Source data
